No Data
Would Jiangxi Fushine Pharmaceutical (SZSE:300497) Be Better Off With Less Debt?
Shareholder Yu Wenjun of jiangxi fushine pharmaceutical (300497.SZ) plans to reduce his shareholding by no more than 0.82%.
Jiangxi Fushine Pharmaceutical (300497.SZ) announced that it holds 17.6218 million shares of the company (excluding buyback...
Jiangxi Fushine Pharmaceutical (300497.SZ): Currently, the company has achieved an annual production capacity of 1200 tons of microbial protein.
On November 14, Gelonghui reported that Jiangxi Fushine Pharmaceutical (300497.SZ) stated on the investor interaction platform that the company plans to establish sales companies for microbial protein in Shanghai and Singapore, intensifying efforts to promote the sales of microbial protein in various sectors of the consumer market. Currently, the company's microbial protein has achieved an annual capacity of 1,200 tons and is constructing a microbial protein production line with a capacity of 0.02 million tons per year. While consolidating technology and production, the company is starting to increase efforts to promote microbial protein in various consumer product marketing strategies. Downstream application scenarios include: health food, functional beverages, dining, special medical food, pet food, and more.
Fushine Pharmaceutical to Set Up Domestic, International Subsidiaries
Jiangxi Fushine Pharmaceutical (300497.SZ) plans to establish subsidiaries in Shanghai and Singapore for the development and sale of Fushine microbiological protein consumer products.
Jiangxi Fushine Pharmaceutical (300497.SZ) announced that, in order to meet the needs of the company's global strategy and accelerate the expansion of microbial proteins...
Jiangxi Fushine Pharmaceutical (300497.SZ): Intends to establish a subsidiary.
Gelonghui November 7th | Jiangxi Fushine Pharmaceutical (300497.SZ) announced that, in order to meet the company's global strategy needs, accelerate the expansion of the microbial protein business market, the company plans to use its own funds to establish Fushine Microbial Protein Application Consumer Products Development and Sales subsidiaries in shanghai and Singapore, with registered capital not exceeding 10 million RMB and 3 million Singapore dollars respectively.
The Market Doesn't Like What It Sees From Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) Revenues YetNo Data
No Data
